US20210369737A1 - Prostate function support formula - Google Patents
Prostate function support formula Download PDFInfo
- Publication number
- US20210369737A1 US20210369737A1 US17/402,229 US202117402229A US2021369737A1 US 20210369737 A1 US20210369737 A1 US 20210369737A1 US 202117402229 A US202117402229 A US 202117402229A US 2021369737 A1 US2021369737 A1 US 2021369737A1
- Authority
- US
- United States
- Prior art keywords
- prostate
- composition
- saw palmetto
- cancer
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Definitions
- the prostate is a gland that is part of the male reproductive system surrounding the urethra at the neck of the bladder.
- the main function of the prostate is to make a thin fluid (semen) that lubricates the urethra and transports sperm.
- men age the prostate loses its original structure and function which may lead to urinary problems.
- Common prostate conditions include prostate cancer which ranks second most common cancer in men. One in seven men will be diagnosed with prostate cancer during his lifetime and is the third leading cause of cancer death in men in the USA (American Cancer Soc. 2017). Symptoms of prostate cancer include difficulty urinating, blood in semen, pelvic and bone pain and erectile dysfunction. Treatment includes radiation therapy, hormone therapy, surgery, chemotherapy, and cryosurgery.
- Benign Prostatic Hypertrophy is another common prostate condition in men, with a prevalence of 50%-60% amongst men 60 years or older and 90% for men 70 years or older (Roehrborn, C. G. “Benign Prostatic Hyperplasia: An Overview”, Reviews in Urology 7, Suppl. 9 (2005) S3-S14). Approximately 14 million men in the United States have symptoms of BPH. Men with symptomatic BPH have a 23% lifetime risk of developing acute urinary retention (AUR) if left untreated (Rosenberg, M. T., et al, “STEP. Simplified Treatment of the Enlarged Prostate”, Int. J. Clin. Pract. (2010), 64(4):488-496). Symptoms of BPH include urinary frequency, nocturia, difficulty urinating, and dribbling. Treatment includes alpha blockers, 5-alpha reductase inhibitors, tadalifil, and surgery.
- Prostatitis the most common urinary tract problem for men younger than age 50 and the third most common urinary tract problem for men older than age 50.
- Symptoms of prostatitis include painful or difficult urination and pain in the groin, pelvic area or genitals.
- Treatment includes antibiotics, alpha blockers, and anti-inflammatory agents.
- the present invention is a dietary supplement to provide prostate function support by safely and effectively supporting prostate health, reduce bladder discomfort and improve urinary flow.
- the present invention is comprised of clinically tested ingredients, including vitamins, minerals, herbs and a proprietary blend of natural ingredients. Drug side effects are not expected since the present invention does not include non-drug ingredients.
- Beta-Sitosterol about 450 mg of Beta-Sitosterol
- the unit dosage form further comprises Vitamin E.
- the unit dosage form further comprises Vitamin B-6
- the unit dosage form further comprises zinc as zinc gluconate.
- the unit dosage form further comprises selenium as amino acid chelate.
- the unit dosage form further comprises copper as copper gluconate.
- the unit dosage form further comprises Quercetin (2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one).
- the unit dosage form further comprises one or more amino acids selected from L-alanine, L-glutamic acid and glycine.
- the unit dosage form further comprises one or more excipients selected from hydroxypropyl methylcellulose, rice concentrate, and silica.
- the unit dosage form further comprises one or more excipients selected from gelatin, magnesium stearate, stearic acid, and microcrystalline cellulose.
- the unit dosage form is formulated as a capsule.
- the invention includes a method to improve prostate function in a man in need thereof comprising administering the unit dosage form of the present invention.
- Applicant has determined that men taking the unit dosage form of the present invention report improvements in prostate function, including decreased bladder discomfort and improved urinary flow.
- FIG. 1 shows ingredients of the present invention: Saw Palmetto, Beta Sitosterol, Quercetin, Stinging Nettle, Pygeum Africanum , and Green Tea;
- FIG. 2 shows ingredients of the present invention: Lycopene, Zinc, Vitamins B6 and E, Amino Acids, Selenium, and Copper;
- FIG. 3 shows a product label for a composition of the invention
- FIG. 4 shows supplement facts of the present invention.
- the term “about” has its generally accepted meaning.
- the term about means ⁇ 10% of the associated value.
- about 100 mg means 100 mg ⁇ 10 mg.
- the term about means ⁇ 5% of the associated value.
- about 100 mg means 100 mg ⁇ 5 mg.
- the term about means ⁇ 2% of the associated value.
- about 100 mg means 100 mg ⁇ 2 mg.
- the term about means ⁇ 1% of the associated value.
- about 100 mg means 100 mg ⁇ 1 mg.
- the present invention is a dietary supplement formulated to support healthy prostate function, reduce bladder discomfort, and promote urinary tract health.
- the individual ingredients of the present invention have demonstrated anti-oxidant, anti-inflammatory, chemopreventative, and immunomodulatory properties in in vitro, in vivo, and/or clinical studies. Both individual and combination of the ingredients have bee n clinically studied in prospective, open label, randomized, interventional or observational studies.
- the recommended dosage for the present invention is 3 tablets per day dosing regimen by oral administration in men.
- a unit dosage form of the invention may contain one or more pharmaceutical diluents or excipients.
- a unit dosage form of the invention may comprise microcrystalline cellulose, silicon dioxide, and magnesium stearate.
- a unit dosage form of the invention comprises one or more excipients selected from hydroxypropyl methylcellulose, rice concentrate, and silica.
- a unit dosage form of the invention comprises one or more excipients selected from gelatin, magnesium stearate, stearic acid, and microcrystalline cellulose.
- the present invention contains Saw Palmetto, a Tier 2 supplement containing fatty acids and beta-sitosterols, commonly used to help men with prostate or urinary symptoms.
- Saw Palmetto has been shown in vivo (rat) to reduce the weight and inhibit growth of prostate (Talpur, N. et al “Comparison of Saw Palmetto, extract and whole berry, and cernitin on prostate growth in rats”, Mol. Cell. Biochem. (2003) 250(1-2):21-26).
- Saw Palmetto is clinically shown to be comparable or more effective than pharmaceutical drugs for pain and urinary symptoms associated with prostatitis and BPH (Cai, T. et al, Int. J. Antimicrob.
- Saw Palmetto may help reduce the pressure that the prostate exerts on the urethra by shrinking the lining of the prostate. Saw Palmetto may reduce cancer cell proliferation and inflammation (Goldmann, W. H. et al, Cell Biol. Int (2001) 25(11):1117-1122; Yang, Y. et al, Intl. Jour. Onc. (2007) 31(3):593-600).
- Beta-sitosterols have been shown clinically to decrease levels of DHT (hormone linked to BPH) and significantly improve urinary flow (Berges, R. R. et al, (Lancet (1995) 345:1529-1532; Klipper, K. F. et al, BR J. Urol. (1997) 80(3):427-432).
- Data comparing men treated with beta-sitosterol to those receiving placebo indicate a significant decrease in symptom scores in the beta-sitosterol group after three and six months of treatment. In a follow-up study, these improvements were maintained for an additional 18 months of observation.
- Stinging Nettle is an herb commonly used to treat urinary problems associated with BPH and urinary tract infections (UTI). Stinging Nettle is clinically shown to relieve difficulty in urinating and urge to urinate caused by BPH (Ghorbanibirgani, A. et al, Iran. Red Cres. Med. J. (2013) 15(1):9-10; Pavone, C. D. et al, Yrologia (2010) 77(1):43-51; Safarinejad, M. R. et al, J. Her. Pharmacother. (2005) 5(4):1-11). In vitro, Stinging Nettle is seen to interfere with SHGB and prevent it from combining with androgens (Nahata, A.
- Stinging Nettle acts a 5- ⁇ -reductase inhibitor, preventing the conversion of testosterone to Dihydrotestosterone (DHT) (Lopatkin, N. et al, World J. Urol. 2005).
- DHT Dihydrotestosterone
- the German Commission E approves the use of nettle leaf as supportive therapy in patients with LUTS (combined with immune and antimicrobial therapy) and to prevent and treat formation of urinary gravel.
- Stinging Nettle leads to significant reduction in IPSS (International Prostate Symptoms Score), serum PSA (prostate specific antigen) and prostate size in a prospective, randomized double blind, placebo controlled cross over clinical trial of 558 men with BPH (Safarinejad, M. R.
- the Stinging Nettle is used as a herb powder.
- Quercetin (CAS Reg. No. 117-39-5), named as 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one, is a plant polyphenol from the flavonoid group, found in many fruits, vegetables, leaves, and grains. Quercetin is a Tier 1 supplement and naturally occurring flavonoid recognized as a potent antioxidant, anti-inflammatory and gives relief of symptoms associated with prostatitis. Quercetin promoted prostate cancer cells apoptosis and caspase activation in vitro (Kim, Y. H. et al, J. Cell. Biochem. (2007) 100(4):998-1009; Lee, D. H. et al, Biochem. Pharmacol.
- Quercetin is effective in vivo in combination with finasteride to reduce prostate weight and anti-tumor activity (Ma, Z. et al, J. Endocrinol. (2004) 181(3):493-507; Ferry, D. R. et al, Clin. Cancer Res. (1996) 2(4):659-668).
- Quercetin is clinically shown to provide symptomatic improvement in CP/CPPS and shown to enhance the efficacy of antibiotic to treat CP when used in combination with other natural ingredients; saw palmetto and stinging nettle (Cai, T. et al, Intl. J. Antimicrob. Agents (2009) 33(6):549-553). Quercetin is a recommended treatment through the UPOINT System for Prostatitis Treatment used by medical professionals (Shoskes, D. A. et al, Urology (2010) 75(6); Shoskes, D. A. et al, Urology (1999) 54(6):960-963) demonstrating decrease in IPSS in a randomized, double-blind, placebo controlled clinical trial. Quercetin has an effect on human prostate tumor in vivo xenografts in mice and inhibits prostate cancer cell proliferation in vitro (Yang, F. et al, Oncology Reports (2016) 35(3):1602-1610).
- Pygeum Africanum is a Tier 2 herb used to promote prostate and bladder health, BPH, and nocturia (also known as nycturia, the need to urinate at night) reduction.
- the major active components of Pygeum Africanum are fat-soluble sterols (phytosterols) and fatty acids that can inhibit the production of DHT (dihydrotestosterone), pro-inflammatory prostaglandins in the prostate (Andro, M. C. et al, Curr. Ther. Res. (1995) 56:796-817; Monograph. “ Pygeum africanum ”, Alternative Medicine Review. (2002) V7(1)), and triterpenes and ferulic acid nesters to block the accumulation of cholesterol in the prostate.
- Pygeum Africanum is shown in vitro and in vivo to modulate bladder contractility, inhibit cancer cell proliferation and viability, promote cell apoptosis, and suppress production of prostaglandins (Levin, R. M. et al, J. Urol. (1996) 156:2084-2088; Santa Maria, M. A., et al, Arch. Esp. Urol. (2003) 56(4):369-378; Boulbes, D. et al, BJU Int. (2006) 98(5):1106-1113; Quiles, M. T. et al, Prostate (2010) 70(10):1044-1053; Papaioannou, M. et al, Invest. New Drugs (2010) 28(6):729-743).
- Green Tea Extract is a Tier 2 supplement with antioxidant qualities to provide support for prostate health, normal prostate size, and anti-cancer protective effect. Green Tea Extract is shown to regulate DHT production and hormones that influence prostate volume. Catechins (polyphenol compounds) in green tea shown to have anti-inflammatory qualities, reduce infection, enhance the immune system, and regulate the production and activities of hormones (Allustr, L. et al, Am. J. Natur. Med. (1996) 5:28-31; Graham, H. N. et al, Prev. Med. (1992) 21:334-350). In vitro, in vivo and clinical studies identified EGCG (green tea catechin) to be a modulator of molecular pathways to prostate carcinogenesis (Nihal, A.
- In vitro EGCG acts as an anti-androgen antagonist, suppresses prostate cancer cell proliferation and production of prostate-specific antigen (PSA), reduces tumor size and delays development of prostate tumors in TRAMP mice (Adhami, V. M. et al, Clin. Cancer Res. (2009) 15(6):1947-1953; Gupta, S. et al, Proc. Natl. Acad. Sci. USA (2001) 98(18):10350-10355; Kim. S. J. et al, Cancer Prev. Res.
- PSA prostate-specific antigen
- Lycopene is a Carotenoid produced by plants. Lycopene enhances antioxidant response to support prostate health and is generally recognized as safe (GRAS).
- GRAS safe
- Epidemiological/Clinical studies link increased lycopene consumption with decreased prostate cancer risk, decreasing serum PSA levels, suppression of tumor growth and supporting urinary function (Obermuller-Jevic, U. C. et al, J. Nutr. 133(11):3356-3360; Ford, N. A. et al, Nutr. Cancer (2011) 63(2):256-263; Yang, C. M. et al, J. Nutr. Biochem. (2012) 23(1):8-17; Zhang, X. et al, Chin. Med. J.
- Lycopene is shown in vitro and in vivo to enhance the antioxidant response of prostate cells, inhibit proliferation, demonstrate chemopreventive effect induce apoptosis and decrease the metastatic capacity of prostate cancer cells and may affect insulin-like growth factor (IGF) intracellular pathway in prostate cancer cells (Konijeti, R. et al, Prostate (2010) 70(14):1547-1554; Kim, H J. S. et al, Nutr. Cancer (2003) 47(1):40-47). Clinical trials with lycopene showed reduction of PSA levels (Kucuk, O. et al, Exp. Biol. Med. (2202) 227(10):881-885; Schwarz, S. 1391(1):49-53; Mohanty, N. K. et al, Urol. Oncol. (2005) 23(6):383-385; Ansari, M. S. et al, BJU Intl. (2003) 92(4):375-378).
- IGF insulin-like growth factor
- Vitamin E and selenium have been shown in vitro and in vivo to reduce risk of prostate cancer, suppress tumor progression and cell apoptosis (Pinto, J. T. et al, Int. J. Cancer (2007) 120(7):1410-1417; Zhang, Y. et al, Proc. Natl. Acad. Sci. USA (2002) 99(11):7408-7413; Limpens, J. et al, J. Nutr. (2006) 136:1287-1293; Malafa, M. et al, Intl. J.
- Vitamin B-6 is required for proper prostate function cell repair and immune health, and the proper manufacture and metabolism of hormones necessary for prostate health.
- Zinc is a Tier 3 supplement for prostatitis, prostate cancer and BPH. Zinc induces apoptosis and antiproliferative effects on prostate cancer and BPH cells in vitro (Costello, L. C. et al, Open Urol. Nephrol. J. (2008) 1; Franklin, R. B. et al, Arch. Biochem. Biophys. (2007) 463(2):211-217. Zinc plays a role in testosterone, sperm formation and motility, and DNA damage repair (Netter, A. et al, Arch. Androl. (1981) 7(1):69-73). Clinical experience associates an inverse relationship between zinc intake and risk of prostate issues (Medarova, Z. et al, Am. J. Cancer Res. (2014) 4(4):385-393; Costello, L. C. et al, Mol. Cancer. (2006) 5:17; Mahmoud, A. M. et al, PLoS ONE (2016) 11.11 e0165956 PMC).
- Zinc gluconate is the zinc salt of gluconic acid. It is an ionic compound consisting of two anions of gluconate for each zinc (II) cation. Zinc gluconate is available from a number of commercial sources.
- “Selenium as an amino acid chelate” is an enhanced form of selenium, a vital trace element nutrient with multiple roles in the growth and functioning of living cells in higher animals and humans.
- Inorganic salt forms of selenium such as sodium selenite and sodium selenite when complexed or incorporated with amino acids, such as aspartic acid and methionine, form selenium-amino acid chelates with enhanced absorption properties.
- Copper gluconate is the copper salt of gluconic acid. It is soluble in water and insoluble in ethanol. Copper gluconate is available from a number of commercial sources.
Abstract
Description
- This is a continuation application of U.S. patent application Ser. No. 16/867,386, filed May 5, 2020; which is a divisional application that claims priority to U.S. patent application Ser. No. 15/829,797 filed on Dec. 1, 2017; the contents of the foregoing of which are herein incorporated by reference in its entirety.
- The prostate is a gland that is part of the male reproductive system surrounding the urethra at the neck of the bladder. The main function of the prostate is to make a thin fluid (semen) that lubricates the urethra and transports sperm. As men age, the prostate loses its original structure and function which may lead to urinary problems. Common prostate conditions include prostate cancer which ranks second most common cancer in men. One in seven men will be diagnosed with prostate cancer during his lifetime and is the third leading cause of cancer death in men in the USA (American Cancer Soc. 2017). Symptoms of prostate cancer include difficulty urinating, blood in semen, pelvic and bone pain and erectile dysfunction. Treatment includes radiation therapy, hormone therapy, surgery, chemotherapy, and cryosurgery.
- Benign Prostatic Hypertrophy (BPH)—Enlarged Prostate is another common prostate condition in men, with a prevalence of 50%-60% amongst men 60 years or older and 90% for men 70 years or older (Roehrborn, C. G. “Benign Prostatic Hyperplasia: An Overview”, Reviews in Urology 7, Suppl. 9 (2005) S3-S14). Approximately 14 million men in the United States have symptoms of BPH. Men with symptomatic BPH have a 23% lifetime risk of developing acute urinary retention (AUR) if left untreated (Rosenberg, M. T., et al, “STEP. Simplified Treatment of the Enlarged Prostate”, Int. J. Clin. Pract. (2010), 64(4):488-496). Symptoms of BPH include urinary frequency, nocturia, difficulty urinating, and dribbling. Treatment includes alpha blockers, 5-alpha reductase inhibitors, tadalifil, and surgery.
- Yet another prostate condition is Prostatitis; the most common urinary tract problem for men younger than
age 50 and the third most common urinary tract problem for men older thanage 50. Symptoms of prostatitis include painful or difficult urination and pain in the groin, pelvic area or genitals. Treatment includes antibiotics, alpha blockers, and anti-inflammatory agents. - A need exists for safe and effective supplements to treat prostate conditions.
- Applicant has determined that the beneficial effects of the present invention, a Prostate Function Support Formula are surprising and unexpected to support and enhance prostate function.
- The present invention is a dietary supplement to provide prostate function support by safely and effectively supporting prostate health, reduce bladder discomfort and improve urinary flow. The present invention is comprised of clinically tested ingredients, including vitamins, minerals, herbs and a proprietary blend of natural ingredients. Drug side effects are not expected since the present invention does not include non-drug ingredients.
- In one embodiment the invention provides a unit dosage form suitable for oral administration in a human comprising:
- about 300 mg of Saw Palmetto;
- about 450 mg of Beta-Sitosterol;
- about 150 mg of Pygeum Africanum;
- about 75 mg of Green Tea extract;
- about 15 mg of Lycopene; and
- about 30 mg of Stinging Nettle.
- In one embodiment, the unit dosage form further comprises Vitamin E.
- In one embodiment, the unit dosage form further comprises Vitamin B-6
- In one embodiment, the unit dosage form further comprises zinc as zinc gluconate.
- In one embodiment, the unit dosage form further comprises selenium as amino acid chelate.
- In one embodiment, the unit dosage form further comprises copper as copper gluconate.
- In one embodiment, the unit dosage form further comprises Quercetin (2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one).
- In one embodiment, the unit dosage form further comprises one or more amino acids selected from L-alanine, L-glutamic acid and glycine.
- In one embodiment, the unit dosage form further comprises one or more excipients selected from hydroxypropyl methylcellulose, rice concentrate, and silica.
- In one embodiment, the unit dosage form further comprises one or more excipients selected from gelatin, magnesium stearate, stearic acid, and microcrystalline cellulose.
- In one embodiment, the unit dosage form is formulated as a capsule.
- The invention includes a method to improve prostate function in a man in need thereof comprising administering the unit dosage form of the present invention.
- Applicant has determined that men taking the unit dosage form of the present invention report improvements in prostate function, including decreased bladder discomfort and improved urinary flow.
-
FIG. 1 shows ingredients of the present invention: Saw Palmetto, Beta Sitosterol, Quercetin, Stinging Nettle, Pygeum Africanum, and Green Tea; -
FIG. 2 shows ingredients of the present invention: Lycopene, Zinc, Vitamins B6 and E, Amino Acids, Selenium, and Copper; -
FIG. 3 shows a product label for a composition of the invention; and -
FIG. 4 shows supplement facts of the present invention. - As used herein, the term “about” has its generally accepted meaning. In one embodiment, the term about means±10% of the associated value. For example, about 100 mg means 100 mg±10 mg. In one embodiment, the term about means±5% of the associated value. For example, about 100 mg means 100 mg±5 mg. In one embodiment, the term about means±2% of the associated value. For example, about 100 mg means 100 mg±2 mg. In one embodiment, the term about means±1% of the associated value. For example, about 100 mg means 100 mg±1 mg.
- The present invention is a dietary supplement formulated to support healthy prostate function, reduce bladder discomfort, and promote urinary tract health.
- Without limiting to any particular mechanism-of-action, the individual ingredients of the present invention have demonstrated anti-oxidant, anti-inflammatory, chemopreventative, and immunomodulatory properties in in vitro, in vivo, and/or clinical studies. Both individual and combination of the ingredients have bee n clinically studied in prospective, open label, randomized, interventional or observational studies.
- The recommended dosage for the present invention is 3 tablets per day dosing regimen by oral administration in men.
- In one embodiment, a unit dosage form of the invention may contain one or more pharmaceutical diluents or excipients. For example, in one embodiment a unit dosage form of the invention may comprise microcrystalline cellulose, silicon dioxide, and magnesium stearate. In another embodiment a unit dosage form of the invention comprises one or more excipients selected from hydroxypropyl methylcellulose, rice concentrate, and silica. In another embodiment a unit dosage form of the invention comprises one or more excipients selected from gelatin, magnesium stearate, stearic acid, and microcrystalline cellulose.
- The present invention contains Saw Palmetto, a Tier 2 supplement containing fatty acids and beta-sitosterols, commonly used to help men with prostate or urinary symptoms. Saw Palmetto has been shown in vivo (rat) to reduce the weight and inhibit growth of prostate (Talpur, N. et al “Comparison of Saw Palmetto, extract and whole berry, and cernitin on prostate growth in rats”, Mol. Cell. Biochem. (2003) 250(1-2):21-26). Saw Palmetto is clinically shown to be comparable or more effective than pharmaceutical drugs for pain and urinary symptoms associated with prostatitis and BPH (Cai, T. et al, Int. J. Antimicrob. Agents (2009) 33(6):549-553; Pais, P. et al, Adv. Ther. (2010) 27(8):555-563; Bondarenko, B. et al, (2003) Phytomedicine). Saw Palmetto may help reduce the pressure that the prostate exerts on the urethra by shrinking the lining of the prostate. Saw Palmetto may reduce cancer cell proliferation and inflammation (Goldmann, W. H. et al, Cell Biol. Int (2001) 25(11):1117-1122; Yang, Y. et al, Intl. Jour. Onc. (2007) 31(3):593-600). Additional clinical studies on Saw Palmettol have shown a statistically significant improvement in urinary symptoms in men with LUTS (Lower urinary tract symptoms), a group of clinical symptoms involving the bladder, urinary sphincter, urethra, and, prostate (Gerber, G. S. et al, Urology (2001) 58960-4, 964-965); progress in CPSI (Chronic Prostitis Symptom Index) scores (Kraychick, S. G. et al, 27th Annual Euro. Assoc. of Urology Cong. Feb. 24-28, 2012, Paris FR), and others (Carraro, J. C. et al, Prostate (1996) 28(4):231-240; Sinescu, I. et al, Urol. Intl. (2011) 86:284-289).
- Beta-sitosterols have been shown clinically to decrease levels of DHT (hormone linked to BPH) and significantly improve urinary flow (Berges, R. R. et al, (Lancet (1995) 345:1529-1532; Klipper, K. F. et al, BR J. Urol. (1997) 80(3):427-432). Data comparing men treated with beta-sitosterol to those receiving placebo indicate a significant decrease in symptom scores in the beta-sitosterol group after three and six months of treatment. In a follow-up study, these improvements were maintained for an additional 18 months of observation.
- Stinging Nettle is an herb commonly used to treat urinary problems associated with BPH and urinary tract infections (UTI). Stinging Nettle is clinically shown to relieve difficulty in urinating and urge to urinate caused by BPH (Ghorbanibirgani, A. et al, Iran. Red Cres. Med. J. (2013) 15(1):9-10; Pavone, C. D. et al, Yrologia (2010) 77(1):43-51; Safarinejad, M. R. et al, J. Her. Pharmacother. (2005) 5(4):1-11). In vitro, Stinging Nettle is seen to interfere with SHGB and prevent it from combining with androgens (Nahata, A. et al, Andrologia (2012) 44:396-409). Stinging Nettle acts a 5-α-reductase inhibitor, preventing the conversion of testosterone to Dihydrotestosterone (DHT) (Lopatkin, N. et al, World J. Urol. 2005). The German Commission E approves the use of nettle leaf as supportive therapy in patients with LUTS (combined with immune and antimicrobial therapy) and to prevent and treat formation of urinary gravel. Stinging Nettle leads to significant reduction in IPSS (International Prostate Symptoms Score), serum PSA (prostate specific antigen) and prostate size in a prospective, randomized double blind, placebo controlled cross over clinical trial of 558 men with BPH (Safarinejad, M. R. et al, J. Her. Pharmacother. (2005) 5(4):1-11). In a similar trial of 100 men with BPH, the treatment group had better effects in relieving clinical symptoms in BPH patients compared to placebo (Ghorbanibirgani, A. et al, Iran. Red Cres. Med. J. (2013) 15(1):9-10). In one embodiment the Stinging Nettle is used as a herb powder.
- Combination therapy clinical studies of Saw Palmetto with Stinging Nettle or Quercetin reduced the symptoms in 85% of LUTS secondary to BPH patients (Pavone, C. D. et al, Yrologia (2010) 77(1):43-51), showed IPSS improvement (Bondarenko, B. et al, (2003) Phytomedicine), was superior to placebo (Lopatkin, N. et al, World J. Urol. 2005), and relieved symptoms of prostatitis (Cai, T. et al, Intl. J. Antimicrob. Agents (2009) 33(6):549-553).
- Quercetin (CAS Reg. No. 117-39-5), named as 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one, is a plant polyphenol from the flavonoid group, found in many fruits, vegetables, leaves, and grains. Quercetin is a
Tier 1 supplement and naturally occurring flavonoid recognized as a potent antioxidant, anti-inflammatory and gives relief of symptoms associated with prostatitis. Quercetin promoted prostate cancer cells apoptosis and caspase activation in vitro (Kim, Y. H. et al, J. Cell. Biochem. (2007) 100(4):998-1009; Lee, D. H. et al, Biochem. Pharmacol. (2008) 75(12):2345-2355; Xing, N. et al, Carcinogenesis (2001) 22:409-414; Wang, G. et al, Oncol. Rep. (2013) 30:357-363). Quercetin is effective in vivo in combination with finasteride to reduce prostate weight and anti-tumor activity (Ma, Z. et al, J. Endocrinol. (2004) 181(3):493-507; Ferry, D. R. et al, Clin. Cancer Res. (1996) 2(4):659-668). Quercetin is clinically shown to provide symptomatic improvement in CP/CPPS and shown to enhance the efficacy of antibiotic to treat CP when used in combination with other natural ingredients; saw palmetto and stinging nettle (Cai, T. et al, Intl. J. Antimicrob. Agents (2009) 33(6):549-553). Quercetin is a recommended treatment through the UPOINT System for Prostatitis Treatment used by medical professionals (Shoskes, D. A. et al, Urology (2010) 75(6); Shoskes, D. A. et al, Urology (1999) 54(6):960-963) demonstrating decrease in IPSS in a randomized, double-blind, placebo controlled clinical trial. Quercetin has an effect on human prostate tumor in vivo xenografts in mice and inhibits prostate cancer cell proliferation in vitro (Yang, F. et al, Oncology Reports (2016) 35(3):1602-1610). - Pygeum Africanum is a Tier 2 herb used to promote prostate and bladder health, BPH, and nocturia (also known as nycturia, the need to urinate at night) reduction. The major active components of Pygeum Africanum are fat-soluble sterols (phytosterols) and fatty acids that can inhibit the production of DHT (dihydrotestosterone), pro-inflammatory prostaglandins in the prostate (Andro, M. C. et al, Curr. Ther. Res. (1995) 56:796-817; Monograph. “Pygeum africanum”, Alternative Medicine Review. (2002) V7(1)), and triterpenes and ferulic acid nesters to block the accumulation of cholesterol in the prostate. Pygeum Africanum is shown in vitro and in vivo to modulate bladder contractility, inhibit cancer cell proliferation and viability, promote cell apoptosis, and suppress production of prostaglandins (Levin, R. M. et al, J. Urol. (1996) 156:2084-2088; Santa Maria, M. A., et al, Arch. Esp. Urol. (2003) 56(4):369-378; Boulbes, D. et al, BJU Int. (2006) 98(5):1106-1113; Quiles, M. T. et al, Prostate (2010) 70(10):1044-1053; Papaioannou, M. et al, Invest. New Drugs (2010) 28(6):729-743). Pygeum Africanum is clinically shown to improve urinary flow, reduce nocturia, and improve prostate symptoms, urinary parameters, and sexual function in men with BPH or prostatitis (Andro, M. C. et al, Curr. Ther. Res. (1995) 56:796-817; Carani, C. et al, Arch. Ital. Urol. Nefrol. Androl. (1991) 63(3)341-345; Chatelain, C. et al, Urology (1999) 54(3):473-478; Barlet, A. et al, Wein Klin. Wochesschr. (1990) 102:667-673; Breza, J. et al, Curr. Med. Res. Opin. (1998) 14(3):127-139).
- Green Tea Extract is a Tier 2 supplement with antioxidant qualities to provide support for prostate health, normal prostate size, and anti-cancer protective effect. Green Tea Extract is shown to regulate DHT production and hormones that influence prostate volume. Catechins (polyphenol compounds) in green tea shown to have anti-inflammatory qualities, reduce infection, enhance the immune system, and regulate the production and activities of hormones (Alschuler, L. et al, Am. J. Natur. Med. (1996) 5:28-31; Graham, H. N. et al, Prev. Med. (1992) 21:334-350). In vitro, in vivo and clinical studies identified EGCG (green tea catechin) to be a modulator of molecular pathways to prostate carcinogenesis (Nihal, A. et al, Nutr. Rev. (1999) 57:78-83; Ahmad, N. et al J. Natl. Cancer Inst. (1997) 89:1881-1886). In vitro EGCG acts as an anti-androgen antagonist, suppresses prostate cancer cell proliferation and production of prostate-specific antigen (PSA), reduces tumor size and delays development of prostate tumors in TRAMP mice (Adhami, V. M. et al, Clin. Cancer Res. (2009) 15(6):1947-1953; Gupta, S. et al, Proc. Natl. Acad. Sci. USA (2001) 98(18):10350-10355; Kim. S. J. et al, Cancer Prev. Res. (2014) 7(4):435-444). Clinically shown in randomized trials to reduce overall rate of progression of prostate cancer in men with HGPIN (high-grade prostatic intraepithelial neoplasia), an abnormality of prostatic glands and believed to precede the development of prostate adenocarcinoma, the most common form of prostate cancer (Kumar, N. B. et al, Cancer Prev. Res. (Phila) (2015) 8(10):879-887; Bettuzzi, S. et al, Cancer Res. (2006) 66(2):1234-1240; Brausi, M. et al, Eur. Urol. (2008) 54(2):472-473). Other clinical trials with great tea and/or its components shown benefits of decreased PSA levels, and other biomarkers correlated with prostate cancer (Henning, S. M. et al, Prostate (2015) 75(5):550-559; McLarty, J. et al, Cancer Prev. Res. (2009) June 19; Nguyen, M. et al, Cancer Prev. Res. (Phila) (2012) 5(2):290-298).
- Lycopene is a Carotenoid produced by plants. Lycopene enhances antioxidant response to support prostate health and is generally recognized as safe (GRAS). Epidemiological/Clinical studies link increased lycopene consumption with decreased prostate cancer risk, decreasing serum PSA levels, suppression of tumor growth and supporting urinary function (Obermuller-Jevic, U. C. et al, J. Nutr. 133(11):3356-3360; Ford, N. A. et al, Nutr. Cancer (2011) 63(2):256-263; Yang, C. M. et al, J. Nutr. Biochem. (2012) 23(1):8-17; Zhang, X. et al, Chin. Med. J. (2010) 123(16):2231-2236; Mariani, S. et al, Int. J. Mol. Sci. (2014) 15(1):143301440; Qiu, X. et al, Cancer Prev. Res. (Phila) (20-13) 6(5):419-427; Tang, Y. et al, Neoplasia (2011) 13(2):108-119; Gann, P. H. et al, Cancer Res. (1999) 59(6):1225-1230). Animal studies show antitumorigenic effect (Yang, C. M. et al, Mol. Nutr. Food Res. (2011) 55(4):606-612; Yang, C. M. et al, J. Nutr. Biochem. (2012) 23(9):1155-1162). Lycopene is shown in vitro and in vivo to enhance the antioxidant response of prostate cells, inhibit proliferation, demonstrate chemopreventive effect induce apoptosis and decrease the metastatic capacity of prostate cancer cells and may affect insulin-like growth factor (IGF) intracellular pathway in prostate cancer cells (Konijeti, R. et al, Prostate (2010) 70(14):1547-1554; Kim, H J. S. et al, Nutr. Cancer (2003) 47(1):40-47). Clinical trials with lycopene showed reduction of PSA levels (Kucuk, O. et al, Exp. Biol. Med. (2202) 227(10):881-885; Schwarz, S. 1391(1):49-53; Mohanty, N. K. et al, Urol. Oncol. (2005) 23(6):383-385; Ansari, M. S. et al, BJU Intl. (2003) 92(4):375-378).
- Vitamin E, an essential vitamin, and Selenium, an essential mineral, have antioxidative properties and are widely used to prevent damage to the cells, tumor suppression in prostate cancer and provide immune support. Vitamin E and selenium have been shown in vitro and in vivo to reduce risk of prostate cancer, suppress tumor progression and cell apoptosis (Pinto, J. T. et al, Int. J. Cancer (2007) 120(7):1410-1417; Zhang, Y. et al, Proc. Natl. Acad. Sci. USA (2002) 99(11):7408-7413; Limpens, J. et al, J. Nutr. (2006) 136:1287-1293; Malafa, M. et al, Intl. J. of Cancer (2006) 118(10):2441-2447). Selenium has shown in vitro to decrease the activity of the androgen receptor leading to apoptosis and growth inhibition on prostate cancer cells, increase levels of p53 (tumor suppression) and regulate oxidative and the immune system (Kong et al, Biomaterials (2011) 32(27):6515-6522; Sarveswaran, S. et al, Int. J. Oncol. (2010) 36(6):1419-1428). Higher blood selenium concentrations have been clinically associated with decreased prostate cancer (EPIC and Physicians' health study) and decrease PSA levels (Clark, L. C. et al, British J. of Urol. 1998) 81:730-734; Allen, N. E. et al, Am. J. Clin. Nutr. (2008) 88(6):1567-1575; Li, H. et al, J. Natl. Cancer Inst. (2004) 96(9):696-703; Meyer, H. A. et al, Cancer Epidemiol. Bioimarkers Prev. (2009) 18(9):2386-2390).
- Vitamin B-6 is required for proper prostate function cell repair and immune health, and the proper manufacture and metabolism of hormones necessary for prostate health.
- Zinc is a
Tier 3 supplement for prostatitis, prostate cancer and BPH. Zinc induces apoptosis and antiproliferative effects on prostate cancer and BPH cells in vitro (Costello, L. C. et al, Open Urol. Nephrol. J. (2008) 1; Franklin, R. B. et al, Arch. Biochem. Biophys. (2007) 463(2):211-217. Zinc plays a role in testosterone, sperm formation and motility, and DNA damage repair (Netter, A. et al, Arch. Androl. (1981) 7(1):69-73). Clinical experience associates an inverse relationship between zinc intake and risk of prostate issues (Medarova, Z. et al, Am. J. Cancer Res. (2014) 4(4):385-393; Costello, L. C. et al, Mol. Cancer. (2006) 5:17; Mahmoud, A. M. et al, PLoS ONE (2016) 11.11 e0165956 PMC). - “Zinc gluconate” is the zinc salt of gluconic acid. It is an ionic compound consisting of two anions of gluconate for each zinc (II) cation. Zinc gluconate is available from a number of commercial sources.
- “Selenium as an amino acid chelate” is an enhanced form of selenium, a vital trace element nutrient with multiple roles in the growth and functioning of living cells in higher animals and humans. Inorganic salt forms of selenium such as sodium selenite and sodium selenite when complexed or incorporated with amino acids, such as aspartic acid and methionine, form selenium-amino acid chelates with enhanced absorption properties.
- “Copper gluconate” is the copper salt of gluconic acid. It is soluble in water and insoluble in ethanol. Copper gluconate is available from a number of commercial sources.
- All publications, patents, and patent documents are incorporated by reference herein, as though individually incorporated by reference. The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention.
Claims (19)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/402,229 US20210369737A1 (en) | 2017-12-01 | 2021-08-13 | Prostate function support formula |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/829,797 US20190167699A1 (en) | 2017-12-01 | 2017-12-01 | Prostate function support formula |
US16/867,386 US11110101B2 (en) | 2017-12-01 | 2020-05-05 | Prostate function support formula |
US17/402,229 US20210369737A1 (en) | 2017-12-01 | 2021-08-13 | Prostate function support formula |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/867,386 Continuation US11110101B2 (en) | 2017-12-01 | 2020-05-05 | Prostate function support formula |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210369737A1 true US20210369737A1 (en) | 2021-12-02 |
Family
ID=66657460
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/829,797 Abandoned US20190167699A1 (en) | 2017-12-01 | 2017-12-01 | Prostate function support formula |
US16/867,386 Active US11110101B2 (en) | 2017-12-01 | 2020-05-05 | Prostate function support formula |
US17/402,229 Pending US20210369737A1 (en) | 2017-12-01 | 2021-08-13 | Prostate function support formula |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/829,797 Abandoned US20190167699A1 (en) | 2017-12-01 | 2017-12-01 | Prostate function support formula |
US16/867,386 Active US11110101B2 (en) | 2017-12-01 | 2020-05-05 | Prostate function support formula |
Country Status (2)
Country | Link |
---|---|
US (3) | US20190167699A1 (en) |
CA (1) | CA3026048A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190167699A1 (en) | 2017-12-01 | 2019-06-06 | Innovus Pharmaceuticals, Inc. | Prostate function support formula |
CA3161779A1 (en) * | 2019-12-19 | 2021-06-24 | An-Katrien VYNCKIER | Compositions and methods for managing infections of a urinary tract |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744161A (en) | 1995-02-24 | 1998-04-28 | Sabinsa Corporation | Use of piperine as a bioavailability enhancer |
US5536506A (en) | 1995-02-24 | 1996-07-16 | Sabinsa Corporation | Use of piperine to increase the bioavailability of nutritional compounds |
EA008596B1 (en) | 2003-04-29 | 2007-06-29 | Пфайзер Инк. | 5,7-DIAMINOPYRAZOLO[4,3-d]PYRIMIDINES USEFUL IN THE TREATMENT OF HYPERTENSION |
US20090143433A1 (en) | 2004-12-01 | 2009-06-04 | Curt Hendrix | Cocktail for modulation of alzheimer's disease |
US20080305096A1 (en) | 2007-06-07 | 2008-12-11 | Unicity International, Inc. | Method and composition for providing controlled delivery of biologically active substances |
US20090197892A1 (en) | 2007-08-21 | 2009-08-06 | Nawaz Ahmad | Anhydrous compositions useful for attaining enhanced sexual wellness |
US8846061B1 (en) * | 2011-03-08 | 2014-09-30 | Mark S. Bezzek | Multivitamin-mineral regimens for longevity and wellness |
EP3049101A4 (en) | 2013-09-27 | 2018-01-10 | Sher, Justin | Nutraceutical compositon for pde4 inhibition, enhanced dopamine metabolism and long term potentiation |
AU2014344740B2 (en) | 2013-11-04 | 2020-03-05 | Atp Institute Pty Ltd | Vasodilator formulation and method of use |
FR3027228B1 (en) | 2014-10-20 | 2016-12-09 | Valbiotis | COMPOSITION COMPRISING A MIXTURE OF PLANT EXTRACTS AND USE FOR ACTING ON GLUCIDIC AND / OR LIPID METABOLISM |
CA3063174A1 (en) | 2017-05-12 | 2018-11-15 | Innovus Pharmaceuticals, Inc. | Therapeutic methods and compositions |
US20190167699A1 (en) | 2017-12-01 | 2019-06-06 | Innovus Pharmaceuticals, Inc. | Prostate function support formula |
-
2017
- 2017-12-01 US US15/829,797 patent/US20190167699A1/en not_active Abandoned
-
2018
- 2018-11-30 CA CA3026048A patent/CA3026048A1/en active Pending
-
2020
- 2020-05-05 US US16/867,386 patent/US11110101B2/en active Active
-
2021
- 2021-08-13 US US17/402,229 patent/US20210369737A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200261474A1 (en) | 2020-08-20 |
CA3026048A1 (en) | 2019-06-01 |
US11110101B2 (en) | 2021-09-07 |
US20190167699A1 (en) | 2019-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mishra et al. | Pharmacological and therapeutic activity of Cissus quadrangularis: an overview | |
US6482447B2 (en) | Method and composition for the treatment of benign prostate hypertrophy (BPH) and prevention of prostate cancer | |
US7597910B2 (en) | Compositions and methods for treating prostate disorders | |
US8247435B2 (en) | Formulations for treating human and animal diseases | |
US20210369737A1 (en) | Prostate function support formula | |
Smolarek et al. | Dietary administration of δ-and γ-tocopherol inhibits tumorigenesis in the animal model of estrogen receptor–positive, but not HER-2 breast cancer | |
EP2285392A2 (en) | Anticancer methods employing extracts of gleditsia sinensis lam | |
Clafshenkel et al. | Morinda citrifolia (Noni) juice augments mammary gland differentiation and reduces mammary tumor growth in mice expressing the unactivated c-erbB2 transgene | |
Xue et al. | Synergism of ellagic acid in combination with radiotherapy and chemotherapy for cancer treatment | |
US8394425B2 (en) | Methods for promoting cellular health and treatment of cancer | |
US8354126B1 (en) | Composition for prostate health | |
US20060009430A1 (en) | Composition for the prevention and treatment of the detrimental effects of dihydrotestosterone | |
US9060959B2 (en) | Synergistic compositions and method for potentiating anti-oxidative activity | |
Oswal et al. | Dietary supplements and medicinal plants in urolithiasis: diet, prevention, and cure | |
US20210100866A1 (en) | Method of treatment using synergistic dietary supplements to relieve physical discomfort and pain, or mental discomfort linked to menstruation | |
US20060246153A1 (en) | Herbal compositions for the teatment and prevention of prostate disorders | |
JP2019504117A (en) | Pharmaceutical composition for the treatment of prostate hyperplasia | |
EP1220676A1 (en) | Prevention of colorectal cancer | |
Alexandrov et al. | Therapeutic effect of iodised serum milk protein, lycopene and their combination on benign prostatic hyperplasia induced in rats | |
Rotimi et al. | Impact of Watermelon (Citrallus lanatus) on Male Fertility | |
Taghipour et al. | The Effects of Clove and Its Constituents on Reproductive System: a Comprehensive Review | |
Abeed et al. | Evaluation of the Potential Protective Role of Galangin Associated with Gold Nanoparticles in the Histological and Functional Structure of Testes of Adult Male Albino Mice Administrated with Carbon Tetrachloride | |
Al-Fartwsy et al. | Ultrastructure of mice testes affected by orally administered crocin of crocus sativus | |
Al-Jeborry et al. | Treatment of Sweating, Hot Flushing and Sleep Disturbance in Peri and Post Menopausal Women with Oral Pometone | |
Woldemeskel | Nutraceuticals in reproductive and developmental disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: INNOVUS PHARMACEUTICALS, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DAMAJ, BASSAM;REEL/FRAME:057226/0862 Effective date: 20180122 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: ECLIPSE BUSINESS CAPITAL LLC (F/K/A ENCINA BUSINESS CREDIT, LLC), AS AGENT, ILLINOIS Free format text: SECURITY INTEREST;ASSIGNORS:INNOVUS PHARMACEUTICALS, INC.;SEMPRAE LABORATORIES, INC.;REEL/FRAME:058789/0001 Effective date: 20220126 |
|
AS | Assignment |
Owner name: AVENUE VENTURE OPPORTUNITIES FUND II, L.P., NEW YORK Free format text: SECURITY INTEREST;ASSIGNOR:INNOVUS PHARMACEUTICALS, INC.;REEL/FRAME:058976/0706 Effective date: 20220101 |